Multiple Myeloma: Use of Bispecifics in Challenging Patient Populations
Before closing out their program on bispecifics in multiple myeloma, expert oncologists consider the value of these agents in more challenging patient populations.
The Evolving Role of Non-BCMA-Targeting Bispecifics in Multiple Myeloma
Following their review of non-BCMA-targeting bispecifics in multiple myeloma, panelists consider practical use of these agents and how they may fit into the real-world treatment paradigm.
Non-BCMA-Targeting Bispecifics in Multiple Myeloma: Cevostamab
A brief discussion on clinical trial data with cevostamab therapy followed by considerations for other non-BCMA-targeted agents being studied in the setting of multiple myeloma.
Non-BCMA-Targeting Bispecifics in Multiple Myeloma: Talquetamab
Switching its focus to non-BCMA-targeting therapies, a panel of experts consider the clinical data behind talquetamab in patients diagnosed with multiple myeloma,
BCMA-Targeting Bispecifics in Multiple Myeloma: Safety Profile
Expert oncologists briefly review safety profiles of BCMA-targeted bispecifics in multiple myeloma and share practical insight on how to mitigate or address toxicities.
Multiple Myeloma: Selecting Among the BCMA-Targeting Therapies
Shared insight on how experts select among the available BCMA-targeting bispecific antibodies and CAR T-cell therapies in patients with multiple myeloma.
The Evolving Role of BCMA-Targeting Bispecifics in Multiple Myeloma
Expert panelists reflect on other clinical trials aimed at defining the role for BCMA-targeting bispecifics in multiple myeloma and consider how they would utilize this class of agents in real-world practice.
BCMA-Targeting Bispecifics in Multiple Myeloma: Teclistamab
Opening its discussion on BCMA-targeting bispecific antibodies in multiple myeloma, a panel of expert oncologists highlights key clinical data behind teclistamab.
Bispecific Antibodies in Relapsed/Refractory MM: Future Perspectives
Closing out their discussion on the treatment paradigm of relapsed/refractory multiple myeloma, key opinion leaders highlight key takeaways and future directions in care.
Appropriate Patient Selection for Cevostamab in Relapsed/Refractory MM
Shared insight on possible real-world applications for FcRH5-targeted bispecific antibody therapy in patients with relapsed/refractory multiple myeloma.
Patient Case 3: Cevostamab in a Patient with MM who Progressed on Multiple Lines of Therapy
Centering discussion on the final patient case, experts review the case of a patient with relapsed/refractory multiple myeloma managed with FcRH5-targeting bispecific cevostamab.
Appropriate Patient Selection for Talquetamab in Relapsed/Refractory MM
Considerations for the integration of GPRC5-targeted therapy into the real-world treatment paradigm of relapsed/refractory multiple myeloma.
Patient Case 2: Managing Heavily Pre-Treated MM With Talquetamab
Switching focus to GPRC5-targeted bispecific antibody therapy, expert hematologist-oncologists review a patient case of relapsed/refractory MM managed with talquetamab.
BCMA-Targeting Bispecific Antibodies in RRMM: Managing ICANS and Infections
Closing out their module on BCMA-targeted therapy in relapsed/refractory MM, panelists highlight the optimal management of ICANS and infections.
BCMA-Targeting Bispecific Antibodies in RRMM: Optimal Management of CRS
Focused discussion from a panel of key opinion leaders on the presence and management of cytokine release syndrome alongside BCMA-targeted therapy in relapsed/refractory MM.
Selecting and Sequencing BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM
Shared insight from expert hematologist-oncologists on the real-world application of teclistamab to improve the management of multiple myeloma.
Overview of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM
A broad perspective on the development of BCMA-targeted bispecific antibodies for patients with relapsed/refractory multiple myeloma.
Patient Case 1: Relapsed/Refractory MM Managed With Teclistamab
Centering discussion on two clinical cases of patients with relapsed/refractory multiple myeloma, expert panelists highlight the use of BCMA-targeted teclistamab in this setting.
Treatment Response and Duration of Therapy in Transplant-Ineligible NDMM
Closing out their module on transplant-ineligible NDMM management, expert panelists consider best practices regarding duration of therapy and adjustments to drug regimens.
Selecting the Optimal Therapy for Patients With Transplant-Ineligible NDMM
Comprehensive discussion on the array of treatment regimens available for patients with transplant-ineligible NDMM and how best to sequence therapy.
Patient Case 3: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Expert oncologists focus on a final patient case of transplant-ineligible newly diagnosed multiple myeloma and reflect on the treatment armamentarium in this setting.
Transplant-Eligible NDMM: Optimizing Therapy for Efficacy and Tolerability
Before closing out their review of treatment for transplant-eligible multiple myeloma, panelists consider how they might adjust therapy to optimize tolerability or efficacy.
Selecting Induction Therapy for Patients With High-Risk Transplant-Eligible NDMM
Shared insight on the optimal selection of induction therapy for patients with high-risk transplant-eligible newly diagnosed multiple myeloma.
Patient Case 2: High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma
Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists define high-risk disease and how it impacts treatment.
Consolidation and Maintenance Therapy in Transplant-Eligible NDMM
A brief discussion on the use of consolidation therapy to improve patient outcomes following transplant in newly diagnosed multiple myeloma.
Selecting the Optimal Induction Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma
Expert perspectives on the real-world use of induction therapy and transplant in patients with transplant-eligible newly diagnosed multiple myeloma.
Recent Updates on Treatment Options for Patients With Transplant-Eligible NDMM
Comprehensive insight on induction therapy regimens in transplant-eligible newly diagnosed multiple myeloma based on the GRIFFIN, MASTER, and DETERMINATION clinical studies.
Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma
Expert panelists review the case of transplant-eligible newly diagnosed multiple myeloma and consider optimal selection of induction therapy.
